CROX
Crocs, Inc.
CROX has the edge over LCID overall, supported by lower modeled downside and stronger fundamentals.
LCID
Lucid Group, Inc.
LCID's outlook is improving, though it still trails on the overall score.
CROX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CROX's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CROX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.4x | $97.23 | -38% |
| Forward | 9.9x | $157 | — |
| Fair | 11x | $146 | -7.1% |
| Current | 12x | $157 | — |
| Expensive | 22x | $286 | +82% |
Historical ranges are pointers, not guarantees.
CROX's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 9.9x next year's earnings.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CROX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CROX, with profitability improving.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CROX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.91 | +21% |
| Q3 2026 | $13.15 | +344% |
| Q2 2026 | $11.33 | +213% |
| Q1 2026 | -$1.62 | -110% |
| Q4 2025 | -$1.50 | -109% |
| Q3 2025 | $2.96 | -79% |
| Q2 2025 | $3.62 | -73% |
| Q1 2025 | $16.21 | +26% |
| Q4 2024 | $15.88 | +24% |
CROX has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CROX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +4.6% |
| Q2 2026 | $1.2B | +2.6% |
| Q1 2026 | $921.5M | -1.7% |
| Q4 2025 | $957.6M | -3.2% |
| Q3 2025 | $996.3M | -6.2% |
| Q2 2025 | $1.1B | +3.4% |
| Q1 2025 | $937.3M | -0.1% |
| Q4 2024 | $989.8M | +3.1% |
CROX's revenue grew through 2023 and has held roughly level since: $1B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +7.2 points |
| Q2 2026 | 24% | +61 points |
| Q1 2026 | 22% | -2 points |
| Q4 2025 | 15% | -4.9 points |
| Q3 2025 | 21% | -4.6 points |
| Q2 2025 | -37% | -67 points |
| Q1 2025 | 24% | -0.3 points |
| Q4 2024 | 20% | -1.6 points |
CROX has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over CROX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CROX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $275.5M | +22% |
| Q2 2026 | $331M | +23% |
| Q1 2026 | -$98.9M | -$16.3M |
| Q4 2025 | $246.4M | -19% |
| Q3 2025 | $226.2M | -19% |
| Q2 2025 | $269.2M | -30% |
| Q1 2025 | -$82.6M | -$39.3M |
| Q4 2024 | $303.4M | -5.3% |
CROX has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CROX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -1.7M shares |
| 1 year | -11% | -6M shares |
| 3 years | -22% | -13.7M shares |
| 5 years | -24% | -15.4M shares |
| Available history | -33% | -23.8M shares |
CROX has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $250M |
| Q2 2026 | $256.2M |
| Q1 2026 | — |
| Q4 2025 | $180.2M |
| Q3 2025 | $208M |
| Q2 2025 | $133.3M |
| Q1 2025 | $60.9M |
| Q4 2024 | $226.3M |
CROX spent $686M buying back its own shares over the past year, up 9.2% from the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CROX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 5.8x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
CROX's net debt is about 1.1 years of its operating earnings (EBITDA), down from 4.2 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CROX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.6 | Neutral |
| Stochastic | 88.0 | Overbought |
CROX's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CROX PE vs Consumer Cyclical Sector
| Metric | CROX | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 34% below |
| PE % | 57 | 47 | 10 pts above |
CROX is trading at 12x earnings, a 34% discount to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CROX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $132.6 | 18% above |
| 20 week MA | $129.2 | 21% above |
| 50 week MA | $109.7 | 43% above |
| 100 week MA | $102.8 | 53% above |
| 200 week MA | $110.2 | 42% above |
CROX has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CROX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.3 | $62.7 | +52% |
| 2021 | $62.7 | $123.5 | +97% |
| 2022 | $123.5 | $103.0 | -17% |
| 2023 | $103.0 | $93.4 | -9.3% |
| 2024 | $93.4 | $110.7 | +19% |
| 2025 | $110.7 | $91.6 | -17% |
| 2026 YTD | $91.6 | $156.9 | +71% |
CROX has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.